| Website | medri.uniri.hr |
|---|---|
| Address | Braće Branchetta 20 51000 Rijeka Croatia |
| Platforms | VIIM |
The Faculty of Medicine of the University of Rijeka (MEDRI) was founded in 1955 and is the oldest and largest constituent of the University of Rijeka. Since its founding, it has grown into an internationally recognised educational and scientific institution. The Faculty of Medicine educates future medical doctors, environmental and public health experts, and pharmacists. The Faculty conducts high-quality and internationally recognised research in several preclinical and clinical areas, such as immunology, virology, microbiology, metabolic diseases, cell growth regulation, and neuroscience.
The Faculty of Medicine’s Center for Proteomics coordinates a national Center of Excellence for virus immunology and vaccines. Our scientists were the first to obtain both ERC Advanced and Proof-of-Concept grants in Croatia (both awarded to Stipan Jonjić, head of the Center of Excellence), for vaccine development, as well as numerous competitive EU and NIH grants.
How can MEDRI help in your vaccine research? Our strength lies in the in vivo testing of new vaccines. MEDRI has extensive experience in animal models of viral and microbial disease and tumours, and long-lasting experience and interest in generating viral vaccine vectors (e.g. based on cytomegalovirus). Our experimental animal facility LAMRI is the largest in this part of Europe, with over 100 conventional and transgenic mouse strains, and has a capacity for more than 20,000 animals in SPF conditions. MEDRI supports our in vivo animal models with state-of-the-art molecular biology tools. Center for Proteomics possesses a state-of-the-art confocal microscope Leica, multiparametric flow cytometer and cell sorter FACSAriaIIu, experience in molecular biology and virology techniques ranging from virus cloning to diagnostics, humanised mouse and mouse xenograft models, and antibody development facility. MEDRI have a bank of over 200 affinity-purified, validated monoclonal antibodies, experience in on-demand antibody generation and testing, and experience in developing diagnostic tools. MEDRI is ISO 9001 certified for the production and purification of murine monoclonal antibodies and holds several patents for antibodies and vaccines. Overall, MEDRI offers an advanced, streamlined pipeline from vaccine development to in vivo validation and molecular elucidation of underlying cellular and molecular mechanisms.
Find out more about MEDRI below.
